HONG KONG SAR - EQS Newswire - 30 December 2025 - Uni-Bio Science Group Limited ("Uni-Bio Science Group", "Uni-Bio" or "the ...

FibroBiologics submits IND application with US FDA to initiate clinical trials of CYPS317 in psoriasis patients: Houston Saturday, January 3, 2026, 11:00 Hrs [IST] FibroBiologics ...

The clinical-stage biotechnology company is seeking regulatory clearance to begin clinical trials of CYPS317, an allogeneic ...

FibroBiologics is pursuing a development program for CYPS317 with the goal of advancing first-in-human clinical trials following FDA review of the IND filing. The IND submission includes comprehensive ...

FibroBiologics (FBLG) announced the filing of a Phase 1/2 Investigational New Drug application with the U.S. Food and Drug Administration seeking ...

HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeuti ...

SOFIE Biosciences doses first patient dosed in phase 3 trials of [18F]FAPI-74, a fluorine-18 labelled radiopharmaceutical targeting FAP for patients with GI cancers: Dulles, Virgi ...

Scientists created a serum containing extracts from a tropical plant and specialized proteins that support hair follicle ...

A plant that grows commonly in tropical areas has emerged as the hope of hair loss people. According to foreign media such as ...

SOFIE Biosciences, an established U.S. manufacturer and developer of radiopharmaceuticals, today announced that the first patient has been dosed in one of its two Phase 3 clinical trials evaluating ...

(Alliance News) - Hutchmed China Ltd on Monday said Chinese regulators have accepted a new drug application for its cancer treatment fanregratinib and granted it priority review status.

NDA supported by results from a Phase II registration trial in China - - Second most common form of liver cancer after hepatocellular carcinoma, with generally poorer long-term survival in comparison ...